Company profile: Purdue Pharma
1.1 - Company Overview
Company description
- Provider of medications and consumer health products for healthcare professionals, patients, consumers, and caregivers; develops, manufactures, and markets prescription opioid analgesics for pain management and over-the-counter medications including laxatives, antiseptics, and dietary supplements; offers public health initiatives; and conducts research and development of medications for cancer and central nervous system disorders.
Products and services
- Prescription Opioid Analgesics: Develops and markets clinical-grade prescription opioid analgesics for pain management, offering medications to healthcare professionals and patients for analgesic use within medical and caregiver settings
- Research and Development: Involved in research-intensive development of new medications for cancer and central nervous system disorders, creating therapeutic products that combine science with care for healthcare professionals and patients
- Over-the-Counter Medications: Offers consumer-grade OTC medications for various health needs, including laxatives, antiseptics, and dietary supplements for patients, consumers, and caregivers
Key contacts
🔒
🔒
Financial details
🔒
1.2 - Competitors and similar companies to Purdue Pharma
Sunovion
HQ: United States
Website
- Description: Provider of therapeutic products discovered, developed and commercialized for central nervous system and respiratory disorders and other illnesses. Portfolio includes Latuda for schizophrenia and bipolar depression; Aptiom for partial-onset seizures; Gemtesa/vibegron for overactive bladder; Myfembree for heavy menstrual bleeding due to uterine fibroids; Orgovyx for advanced prostate cancer; LUNESTA; and XOPENEX.
- Rationale: This competitor operates in a highly similar market segment with overlapping features.
- Company type: Private company
- Employees: ●●●●●
- Total funding raised: $●●●m
- Backers: ●●●●●●●●●●
- Acquisitions: ●●
View full Sunovion company profile →
Harbor Therapeutics
HQ: United States
Website
- Description: Provider of a proprietary class of adrenal steroid hormones developed as novel pharmaceuticals and potential nutraceuticals for human health.
- Rationale: This competitor operates in a highly similar market segment with overlapping features.
- Company type: Private company
- Employees: ●●●●●
- Total funding raised: $●●●m
- Backers: ●●●●●●●●●●
- Acquisitions: ●●
View full Harbor Therapeutics company profile →
Arrowhead Pharmaceuticals
HQ: United States
Website
- Description: Provider of RNAi therapeutics for genetically driven diseases with protein overproduction, leveraging the TRiM platform for ligand-mediated, tissue-specific delivery. Pipeline includes plozasiran (ARO-APOC3) for hypertriglyceridemia, zodasiran (ARO-ANG3) for mixed dyslipidemia, and ARO programs targeting RAGE, MUC5AC, and MMP7 for inflammatory and muco-obstructive lung diseases and idiopathic pulmonary fibrosis.
- Rationale: This competitor operates in a highly similar market segment with overlapping features.
- Company type: Private company
- Employees: ●●●●●
- Total funding raised: $●●●m
- Backers: ●●●●●●●●●●
- Acquisitions: ●●
View full Arrowhead Pharmaceuticals company profile →
Medarex
HQ: United States
Website
- Description: Provider of fully human antibody-based therapeutics, focused on discovering, developing and commercializing treatments for life-threatening and debilitating diseases, including cancer, inflammation, autoimmune disorders and infectious diseases, leveraging its UltiMAb technology.
- Rationale: This competitor operates in a highly similar market segment with overlapping features.
- Company type: Private company
- Employees: ●●●●●
- Total funding raised: $●●●m
- Backers: ●●●●●●●●●●
- Acquisitions: ●●
View full Medarex company profile →
Ascendis Pharma
HQ: United States
Website
- Description: Provider of the TransCon prodrug technology platform, which transiently conjugates an inert carrier to a parent drug for systemic or localized release, and a pipeline of investigational therapies: TransCon hGH for growth hormone deficiency, TransCon PTH for hypoparathyroidism, TransCon CNP for achondroplasia, and oncology candidates TransCon TLR7/8 Agonist and TransCon IL-2 β/γ.
- Rationale: This competitor operates in a highly similar market segment with overlapping features.
- Company type: Private company
- Employees: ●●●●●
- Total funding raised: $●●●m
- Backers: ●●●●●●●●●●
- Acquisitions: ●●
View full Ascendis Pharma company profile →
🔒
2.M&A buyers
2.1 Potential strategic acquirers in the sector
🔒
🔒
🔒
🔒
View all strategic buyers with complete profiles
Start Free Trial →
2.2 - Strategic buyer groups for Purdue Pharma
🔒
Buyer group 1: ████████ ████████
●● companies
Description: ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████
Key Products: ████████, ████████, ████████, ████████
🔒
View all companies in this group
Request Free Trial Now →
🔒
Buyer group 2: ████████ ████████
●● companies
Description: ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████
Key Products: ████████, ████████, ████████, ████████
🔒
View all companies in this group
Request Free Trial Now →
🔒
Buyer group 3: ████████ ████████
●● companies
Description: ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████
Key Products: ████████, ████████, ████████, ████████
🔒
View all companies in this group
Request Free Trial Now →
🔓 Unlock all detailed buyer group breakdowns with complete company profiles
Start Free Trial →
3. Investors and private equity firms
3.1 - Buyout funds investing in similar companies to Purdue Pharma
2.2 - Growth funds investing in similar companies to Purdue Pharma
🔒
View all growth equity funds with complete profiles
Start Free Trial →
4 - Top valuation comps for Purdue Pharma
4.2 - Public trading comparable groups for Purdue Pharma
🔓 Unlock all public trading comparable groups with complete valuation data
Start Free Trial →